Physician profile
Hong X Vo
NPI 1447419940
$90,591.49
in general payments reported to CMS, 2019-2025
27 companies · $20K in 2025
The $20K reported for 2025 was more than what 96% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $643 · 2020: $284 · 2021: $1,103 · 2022: $14K · 2023: $33K · 2024: $22K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $67K · Food and Beverage: $4,717 · Travel and Lodging: $2,886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $66,668.75 |
| Food and Beverage | $4,717.44 |
| Travel and Lodging | $2,886.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $87,026.36 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Pacira Therapeutics, INC. | $706.71 | 2019-2021 | |
| Allergan, INC. | $360.48 | 2019-2022 | |
| Abbott Laboratories | $314.83 | 2019-2025 | Proclaim, Octrode |
| Pfizer INC. | $263.72 | 2019-2024 | |
| Ipsen Biopharmaceuticals, INC | $246.89 | 2024-2025 | Dysport |
| Lilly USA, LLC | $239.10 | 2022-2024 | Emgality, Reyvow |
| Medtronic, INC. | $200.10 | 2023 | Vanta Adaptivestim |
| Boston Scientific Corporation | $159.71 | 2019-2025 | Wavewriter Alpha Prime 16 |
| Stratus Medical, LLC | $143.38 | 2025 | Nimbus |
| Mallinckrodt Enterprises LLC | $120.30 | 2019 | |
| Spinefrontier, INC. | $106.62 | 2024 | Inspan, Sijfuse |
| Grt US Holding, INC. | $106.55 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $104.34 | 2023-2024 | Iovera, Zilretta |
| Depuy Synthes Sales INC. | $87.53 | 2019-2025 | Monovisc, Orthovisc |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heron Therapeutics, INC. | $69.07 | 2021 | |
| Lundbeck LLC | $57.02 | 2024-2025 | Vyepti |
| Bioventus LLC | $56.71 | 2021-2022 | |
| Bausch Health US, LLC | $47.70 | 2019 | |
| Painteq LLC | $38.35 | 2023-2024 | Painteq |
| Mdd US Operations, LLC | $36.07 | 2019-2021 | |
| Agile Therapeutics, INC. | $21.47 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $18.06 | 2021 | |
| Medtronic USA, INC. | $17.56 | 2019 | |
| Averitas Pharma INC. | $16.28 | 2023 | Qutenza |
| Saluda Medical Americas, INC. | $14.24 | 2022 | |
| Fidia Pharma USA INC. | $12.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hong Vo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.